We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...
Grifols revenue and EBITDA growth, improved leverage ratio, and significant liquidity highlight its resilience and potential ...
Hikma's generics business, grew 9 per cent to $1.026 billion, surpassing the $1 billion revenue mark for the first time.
Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing ...
Robust financial performance driven by full year 2024 royalty revenue growth of 28%Reiterating 2025 financial guidance of $180-$200 million in ...
(NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported financial results for the year ended December 31, 2024 and highlighted recent ...
Ligand Pharmaceuticals Incorporated ( NASDAQ: LGND) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET ...
Company Announcement Nanoform Finland Plc February 27, 2025 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform 2024 report: Deal discussions around product kernels intensify After a strong ...
The Institute is delighted to welcome four new Non-Executive Directors to the Board of Babraham Institute Enterprise (BIE) ...
Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and year ended December 31, 2024, and provided business highlights. “In 2024, we made significant ...
The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...
A progressive approach to drug approval would balance the reality of drug safety and efficacy research with the desire to get ...